YM-900 | CAS#143151-35-3 | AMPA Receptor Antagonist

MedKoo Cat#: 526938 | Name: YM-900

Description:

WARNING: This product is for research use only, not for human or veterinary use.

YM-900, also known as YM-90K, is an AMPA receptor antagonist and glutamate receptor antagonist potentially for the treatment of stroke.

Chemical Structure

YM-900

CAS#143151-35-3

Theoretical Analysis

MedKoo Cat#: 526938

Name: YM-900

CAS#: 143151-35-3

Chemical Formula: C11H7N5O4

Exact Mass: 273.0498

Molecular Weight: 273.21

Elemental Analysis: C, 48.36; H, 2.58; N, 25.63; O, 23.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

YM-90K; YM-900; YM90K; YM900; YM 90K; YM 900.

IUPAC/Chemical Name

6-(1H-imidazol-1-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione

InChi Key

GBWIZNYOJITVFI-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H7N5O4/c17-10-11(18)14-7-4-9(16(19)20)8(3-6(7)13-10)15-2-1-12-5-15/h1-5H,(H,13,17)(H,14,18)

SMILES Code

O=C1NC2=C(C=C(N3C=CN=C3)C([N+]([O-])=O)=C2)NC1=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 273.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hashimoto T, Narikawa S, Huang XL, Minematsu T, Usui T, Kamimura H, Endou H. Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab Dispos. 2004 Oct;32(10):1096-102. PubMed PMID: 15377641. 2: Iwasaki K, Chung EH, Egashira N, Hatip-Al-Khatib I, Mishima K, Egawa T, Irie K, Fujiwara M. Non-NMDA mechanism in the inhibition of cellular apoptosis and memory impairment induced by repeated ischemia in rats. Brain Res. 2004 Jan 2;995(1):131-9. PubMed PMID: 14644478. 3: Katsuta K, Umemura K, Ueyama N, Matsuoka N. Pharmacological evidence for a correlation between hippocampal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur J Pharmacol. 2003 Apr 25;467(1-3):103-9. PubMed PMID: 12706462. 4: Nakano M, Ueda H, Li JY, Matsumoto M, Yanagihara T. A potent AMPA/kainate receptor antagonist, YM90K, attenuates the loss of N-acetylaspartate in the hippocampal CA1 area after transient unilateral forebrain ischemia in gerbils. Life Sci. 2001 Sep 14;69(17):1983-90. PubMed PMID: 11589513. 5: Turski L, Schneider HH, Neuhaus R, McDonald F, Jones GH, Löfberg B, Schweinfurth H, Huth A, Krüger M, Ottow E. Phosphonate quinoxalinedione AMPA antagonists. Restor Neurol Neurosci. 2000;17(1):45-59. PubMed PMID: 11490077. 6: Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S. Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10. PubMed PMID: 11354378. 7: Nikam SS, Kornberg BE. AMPA receptor antagonists. Curr Med Chem. 2001 Feb;8(2):155-70. Review. PubMed PMID: 11172672. 8: Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S. 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. PubMed PMID: 10843235. 9: Mignani S, Bohme GA, Boireau A, Cheve M, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Stutzmann JM. 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. Bioorg Med Chem Lett. 2000 Mar 20;10(6):591-6. PubMed PMID: 10741560. 10: Shirane M, Nakamura K. Group II metabotropic glutamate receptors are a common target of N-anisoyl-GABA and 1S,3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP. Neuropharmacology. 2000 Mar 3;39(5):866-72. PubMed PMID: 10699452. 11: YM 900. YM 90K. Drugs R D. 1999 Jan;1(1):42-3. PubMed PMID: 10565984. 12: Kodama M, Yamada N, Sato K, Kitamura Y, Koyama F, Sato T, Morimoto K, Kuroda S. Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. Eur J Pharmacol. 1999 Jun 11;374(1):11-9. PubMed PMID: 10422635. 13: Shimojo M, Takasugi K, Yamamoto I, Funato H, Mochizuki H, Kohsaka S. Neuroprotective action of a novel compound--M50463--in primary cultured neurons. Brain Res. 1999 Jan 2;815(1):131-9. PubMed PMID: 9974133. 14: Arias RL, Tasse JR, Bowlby MR. Neuroprotective interaction effects of NMDA and AMPA receptor antagonists in an in vitro model of cerebral ischemia. Brain Res. 1999 Jan 23;816(2):299-308. PubMed PMID: 9878799. 15: Boireau A, Meunier M, Imperato A. Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole. J Pharm Pharmacol. 1998 Nov;50(11):1293-7. PubMed PMID: 9877317. 16: Takamatsu H, Kondo K, Ikeda Y, Umemura K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol. 1998 Dec 4;362(2-3):137-42. PubMed PMID: 9874163. 17: Li H, Matsumoto K, Watanabe H. An alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist and an N-methyl-D-aspartate (NMDA) channel blocker synergistically impair spatial memory in rats. Biol Pharm Bull. 1998 Nov;21(11):1228-30. PubMed PMID: 9853420. 18: Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, Shimizu-Sasamata M, Yamaguchi T. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):586-91. PubMed PMID: 9840429. 19: Kawasaki-Yatsugi S, Shimizu-Sasamata M, Yatsugi S, Yamaguchi T. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats. J Pharm Pharmacol. 1998 Aug;50(8):891-8. PubMed PMID: 9751454. 20: Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura J, Inami H, Sakamoto S, Yamaguchi T. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol. 1998 Jul;50(7):795-801. PubMed PMID: 9720630.